Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

What a brutal six months it’s been for Insulet. The stock has dropped 33.8% and now trades at $204.57, rattling many ...

Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over ...

PODD is Intuitive Surgical’s counterpart in the Health Care Equipment sector that has: 1) A lower valuation (P/OpInc) in comparison to Intuitive Surgical stock 2) However, it exhibits higher revenue ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

Insulet Corp. closed 41.66% below its 52-week high of $354.88, which the company reached on November 20th.

Parnassus Investments, an investment management company, released the “Parnassus Mid Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Following a robust ...

Fintel reports that on May 7, 2024, Wolfe Research upgraded their outlook for Insulet (NasdaqGS:PODD) from Peer Perform to Outperform. As of May 2, 2024, the average one-year price target for Insulet ...

Insulet (NasdaqGS:PODD) initiated a voluntary Medical Device Correction for certain Omnipod 5 Pods after identifying a manufacturing issue that can lead to insulin under delivery. The issue is linked ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on ...